AbbVie Inc. (ABBV)
Summary
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 58,517 | $10.28M | $14.46M | $4.18M | 40.68% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 28,579 | $4.15M | $7.06M | $2.91M | 70.23% |
| MSH Michelle S. Hickox FIRST FINANCIAL BANKSHARES Inc. | 4,410 | $736,792.27 | $1.09M | $352,918.73 | 47.9% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 10,731 | $1.87M | $2.65M | $782,133.61 | 41.83% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 16,876 | $1.72M | $4.17M | $2.45M | 141.83% |
AbbVie Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GM Geoff Meacham B of A Securities | 72.26 | $17,920.11 | $18,381.84 | $461.73 | 2.58% |
| EDS Evan David Seigerman BMO Capital | 134.41 | $33,333.33 | $34,471.77 | $1,138.44 | 3.42% |
| TH Trung Huynh UBS | 131.89 | $32,708.18 | $33,301.68 | $593.5 | 1.81% |
AbbVie Inc. (ABBV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AbbVie Inc. ever had a stock split?
AbbVie Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | NYSE Exchange | 00287Y109 CUSIP |
| BR Country | 57,000 Employees | 15 Jul 2026 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
Overview
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.
Products and Services
- Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
- Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
- Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
- Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
- Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
- Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
- Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
- Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
- Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
- Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
- Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
- Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
- Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
- Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
- Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
- Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
- Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
- Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.
